Sign inJoin waitlistJoin the waitlist

Jonathon Cohen

Co-Director, Lymphoma Program · Winship Cancer Institute at Emory Midtown

Credentials: · · · · ·

History

Lymphoma Program · Winship Cancer Institute at Emory Midtown
Present
Winship Cancer Institute at Emory Midtown · Emory University School of Medicine
Present

Ohio State University College of Medicine
2010–2013
Internal Medicine
Ohio State University College of Medicine
2007–2010
MS from The Ohio State University
University of Florida College of Medicine
2003–2007
Emory University
1999–2003

Research

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
The Lancet Oncology · 2016 · 758 citations
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II…
Journal of Clinical Oncology · 2018 · 568 citations
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
The Lancet · 2021 · 391 citations

Christopher Flowers
57 papers
BK
Brad Kahl
40 papers
Reem Karmali
30 papers
SB
Stefan Barta
28 papers · 1 as a fellow
Narendranath Epperla
26 papers
Peter Martin
26 papers
TF
Timothy Fenske
25 papers
Kami Maddocks
24 papers
Brian Hill
23 papers
AD
Alexey Danilov
21 papers
Kristie Blum
21 papers
Thomas Habermann
21 papers

Grants

Increasing Participation in NCI-Funded Clinical Trials at Winship Cancer Institute
National Cancer Institute · R50
Contact PI · $626.4K · Emory University
2023–2028

Clinical trials

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Principal investigator · Recruiting · Phase 2
Emory University
2021–2027
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Principal investigator · Active not recruiting · Phase 2
Emory University
2019–2026
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Principal investigator · Completed · Phase 1, Phase 2
Emory University
2018–2025
Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission
Principal investigator · Unknown · Phase 1, Phase 2
Emory University
2016–2024